Atomo is scaling up HIV Self-Testing across Australia. - National mail-out program to generate $1.3M over 2 years - Expanding vending machine pilots nationwide - Supporting NSW Health’s new "MyTest" initiative Read more: bit.ly/3Ro0OPG #HIVTesting #PublicHealth

New agreement | FebriDx® is now available to health care practitioners in Australia and New Zealand, following the signing of a distribution agreement with Regional Health Care Group (RHCG), a Henry Schein company. Read the ASX release: bit.ly/LDX-AU-NZ $LDX #LDX #Lumos

On Monday, Atomo was privileged to attend the official launch event for the #MyTest Vending Machine Program at NSW Health We are incredibly proud to be contributing to the effort to eliminate HIV in Australia with the supply of our HIV Self Test to the NSW MoH for this program

$LDX | Lumos Diagnostics has extended its agreement with Henry Schein Europe, which will see the expansion of distribution of FebriDx® into Belgium. Read the ASX release bit.ly/LDX-Belgium #Lumos #healthcare #pointofcare #diagnostics #AMR #antimicrobialresistance #innovation

Atomo Diagnostics is pleased to share its results for Q4 FY24 this Thursday, July 25 at 11:00am AEST. Join CEO John Kelly then by registering at the link below. Please submit all questions in advance to [email protected] bit.ly/46aRHZ3

Are you attending the Association for Diagnostics & Laboratory Medicine #ADLM Conference beginning this weekend? Keep an eye out for #AtomoDiagnostics CEO, John Kelly, who will be talking all things diagnostics in Chicago. For more information about our world-leading diagnostic solutions, visit bit.ly/4d8PBeb

Are you attending the Association for Diagnostics & Laboratory Medicine #ADLM Conference beginning this weekend? Keep an eye out for #AtomoDiagnostics CEO, John Kelly, who will be highlighting our swab-based testing solutions. For more information about our Curie platform, visit bit.ly/3A0qRXf

The Association for Diagnostics & Laboratory Medicine #ADLM Conference is just a couple of days away, and we would like to remind attendees to keep an eye out for our CEO, John Kelly. For more information on our cassette's compatibility with a wide range of desktop reader systems, visit bit.ly/4f6UTZG

ICYMI: Before jet-setting to the U.S for the Association for Diagnostics & Laboratory Medicine Conference this past weekend, Atomo's CEO John Kelly presented Atomo's Q4 FY24 results via webinar. If you would like to view the webinar, please click the link below. youtube.com/watch?v=S_D7Bf…

Atomo CEO John Kelly is heading to the NextGen Dx event in Washington D.C. this weekend to discuss how our Pascal cassette surpasses traditional RDT kits in all aspects. To meet John at NextGen Dx, email [email protected] or visit bit.ly/3SJmJ4B

Meet us at NextGen Dx to learn how Atomo elevates rapid diagnostic test solutions. Our award-winning poster shows Pascal reduces error rates vs. traditional kits, boosting usability and accuracy. Email [email protected] or visit bit.ly/4fzzAjF for a meeting

Attending NextGen Dx? Meet with us to learn why Atomo's test platforms are top-notch! Pascal achieved 96% validity vs. 42% for traditional kits in an independent study. Book a meeting by emailing [email protected] or visiting bit.ly/4fFitga

Just 3 days until NextGen Dx in D.C.! We're excited to showcase our award-winning poster and why 90% of users prefer Atomo’s solutions. Independent studies show Pascal saves time and simplifies testing. Meet our CEO John Kelly by visiting bit.ly/4dypXjq

$LDX | #Lumos has been awarded placement of their novel POC test, FebriDx®, on the MediGroup national contract, making it available to all their members in the United States (US). Read the ASX release: bit.ly/LDX-MediGroup #LDX #pointofcare #diagnostics #rapidtest #respiratory

$LDX | #Lumos has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to support the planned CLIA-waiver clinical study and regulatory submission for Lumos’ FebriDx® bacterial/non-bacterial test. Read the ASX release: bit.ly/LDX_BARDA

$LDX | #Lumos has successfully completed the retail component of its Entitlement Offer, which raised approximately A$6.9 million, bringing the total amount raised under the Entitlement Offer to A$10.0 million. Read the ASX release: bit.ly/LDX-Retail-Off… #LDX #healthcare #AMR

Atomo is pleased to announce receiving a $2.44 million Government CRC-P grant to spearhead the development of a groundbreaking rapid test for active syphilis diagnosis.  Read more bit.ly/4eV5Rkm

MEDIA | #Lumos was featured on Channel 9 News during its prime time 6pm national bulletin last night, showcasing our FebriDx® rapid diagnostic test that helps healthcare professionals make informed decisions about #antibiotic prescribing. bit.ly/LDX-Nine-News-… $LDX #LDX #AMR

Milestone | Lumos has has received approval from the Centers for Medicare and Medicaid Services (CMS) Panel for the FebriDx PLA (0442U) code to be reimbursed at a rate of US$41.38/test. Read the ASX Release: bit.ly/LDX-CPT-PLA $LDX #LDX #Lumos #pointofcare #diagnostics

$LDX DEAL | #Lumos Diagnostics has signed a transformational US distribution deal with PHASE Scientific for FebriDx® worth up to US$317m over six years. Read today's #ASX release: bit.ly/LDX_Phase_Scie… #innovation #biotech #healthcare #pointofcare